Diaceutics (LON:DXRX) Sets New 52-Week High – Still a Buy?

Diaceutics PLC (LON:DXRX)’s stock price reached a new 52-week high during trading on Wednesday . The company traded as high as GBX 151 ($1.84) and last traded at GBX 145.50 ($1.78), with a volume of 416157 shares. The stock had previously closed at GBX 137.50 ($1.68).

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on DXRX. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($1.95) target price on shares of Diaceutics in a research note on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and set a GBX 160 ($1.95) price objective on shares of Diaceutics in a report on Tuesday, December 17th.

Diaceutics Price Performance

The company has a quick ratio of 9.92, a current ratio of 4.85 and a debt-to-equity ratio of 2.93. The firm’s fifty day moving average price is GBX 122.89 and its 200-day moving average price is GBX 126.77. The stock has a market cap of £122.90 million, a P/E ratio of -4,850.00 and a beta of 0.58.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.